Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Crawford, Anatasha C ^a   Riggins, Rebecca B ^a   Shajahan, Ayesha N ^a   Zwart, Alan ^a   Clarke, Robert ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; BECLIN 1; FULVESTRANT; PROTEIN BCL 2; PROTEIN BCL W; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; APOPTOSIS REGULATORY PROTEIN; BCL2L2 PROTEIN, HUMAN; DRUG DERIVATIVE; ESTRADIOL; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NECROSIS; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CELL LINE, TUMOR; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; HUMANS; NECROSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING;

EID: 77649116895     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008604     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
2. Howell A, Robertson JF, Quaresma AJ, Aschermannova A, Mauriac L, et al. (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396-3403.
3. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, et al. (2002) Doubleblind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20: 3386-3395.
4. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, et al. (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22: 7316-7339.
5. Clarke R, Leonessa F, Welch JN, Skaar TC (2001) Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53: 25-71.
6. O'Reilly LA, Print C, Hausmann G, Moriishi K, Cory S, et al. (2001) Tissue expression and subcellular localization of the pro-survival molecule Bcl-w. Cell Death Differ 8: 486-494.
7. Yan W, Samson M, Jegou B, Toppari J (2000) Bcl-w forms complexes with Bax and Bak, and elevated ratios of Bax/Bcl-w and Bak/Bcl-w correspond to spermatogonial and spermatocyte apoptosis in the testis. Mol Endocrinol 14: 682-699.
8. Kroemer G (1997) The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 3: 614-620.
9. Yang E, Korsmeyer SJ (1996) Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 88: 386-401.
10. Huang Z (2000) Bcl-2 family proteins as targets for anticancer drug design. Oncogene 19: 6627-6631.
11. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G (2007) Self-eating and selfkilling: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8: 741-752.
12. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, et al. (2005) Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122: 927-939.
13. Furuya N, Yu J, Byfield M, Pattingre S, Levine B (2005) The evolutiona1rily conserved domain of Beclin 1 is required for Vps34 binding, autophagy and tumor suppressor function. Autophagy 1: 46-52.
14. Clarke R, Shajahan AN, Riggins R, Cho Y, Crawford AC, et al. (2009) Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. J Steroid Biochem Mol Biol 114: 8-20.
15. Bursch W, Ellinger A, Kienzl H, Torok L, Pandey S, et al. (1996) Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 17: 1595-1607.
16. Qadir MA, Kwok B, Dragowska WH, To KH, Le D, et al. (2008) Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast Cancer Res Treat 112: 389-403.
17. Abedin MJ, Wang D, McDonnell MA, Lehmann U, Kelekar A (2007) Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ 14: 500-510.
18. Cui Q, Tashiro S, Onodera S, Minami M, Ikejima T (2007) Autophagy preceded apoptosis in oridonin-treated human breast cancer MCF-7 cells. Biol Pharm Bull 30: 859-864.
19. Brunner N, Boulay V, Fojo A, Freter CE, Lippman ME, et al. (1993) Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res 53: 283-290.
20. Clarke R, Brünner N, Thompson EW, Glanz P, Katz D, et al. (1989) The interrelationships between ovarian-independent growth, antiestrogen resistance and invasiveness in the malignant progression of human breast cancer. J Endocrinol 122: 331-340.
21. Brünner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, et al. (1997) MCF7/LCC9: an antiestrogen resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early crossresistance to the non-steroidal antiestrogen tamoxifen. Cancer Res 57: 3486-3493.
22. Zhai D, Jin C, Satterthwait AC, Reed JC (2006) Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 13: 1419-1421.
23. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, et al. (2008) Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4: 151-175.
24. Kessel D, Reiners JJ Jr (2007) Initiation of apoptosis and autophagy by the Bcl-2 antagonist HA14-1. Cancer Lett 249: 294-299.
25. Bauvy C, Gane P, Arico S, Codogno P, Ogier-Denis E (2001) Autophagy delays sulindac sulfide-induced apoptosis in the human intestinal colon cancer cell line HT-29. Exp Cell Res 268: 139-149.
26. Dowsett M, Goldhirsch A, Hayes DF, Senn HJ, Wood W, et al. (2007) International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 9: R81.
27. Thompson A, Brennan K, Cox A, Gee J, Harcourt D, et al. (2008) Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res 10: R26.
28. Gee JM, Robertson JF, Ellis IO, Willsher P, McClelland RA, et al. (1994) Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619-628.
29. Cameron DA, Keen JC, Dixon JM, Bellamy C, Hanby A, et al. (2000) Effective tamoxifen therapy of breast cancer involves both antiproliferative and proapoptotic changes. Eur J Cancer 36: 845-851.
30. Ellis PA, Smith IE, Detre S, Burton SA, Salter J, et al. (1998) Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 48: 107-116.
31. Gu Z, Lee RY, Skaar TC, Bouker KB, Welch JN, et al. (2002) Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to faslodex (ICI 182,780). Cancer Res 62: 3428-3437.
32. Riggins R, Zwart A, Nehra R, Agarwal P, Clarke R (2005) The NFkB inhibitor parthenolide restores ICI 182,780 (Faslodex; Fulvestrant)-induced apoptosis in antiestrogen resistant breast cancer cells. Mol Cancer Ther 4: 33-41.
33. Gomez BP, Riggins R, Shajahan AN, Klimach U, Wang A, et al. (2007) Human X-Box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J 21: 4013-4027.
34. Wilson JW, Nostro MC, Balzi M, Faraoni P, Cianchi F, et al. (2000) Bcl-w expression in colorectal adenocarcinoma. Br J Cancer 82: 178-185.
35. Yao M, Nguyen TV, Pike CJ (2007) Estrogen regulates Bcl-w and Bim expression: role in protection against beta-amyloid peptide-induced neuronal death. J Neurosci 27: 1422-1433.
36. Kim R, Emi M, Tanabe K, Toge T (2004) Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 101: 2491-2502.
37. Real PJ, Cao Y, Wang R, Nikolovska-Coleska Z, Sanz-Ortiz J, et al. (2004) Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. Cancer Res 64: 7947-7953.
38. Erlich S, Mizrachy L, Segev O, Lindenboim L, Zmira O, et al. (2007) Differential interactions between Beclin 1 and Bcl-2 family members. Autophagy 3: 561-568.
39. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ (2007) Potential therapeutic applications of autophagy. Nat Rev Drug Discov 6: 304-312.
40. Sung KF, Odinokova IV, Mareninova OA, Rakonczay Z Jr, Hegyi P, et al. (2009) Prosurvival Bcl-2 proteins stabilize pancreatic mitochondria and protect against necrosis in experimental pancreatitis. Exp Cell Res 315: 1975-1989.
41. Ullman E, Fan Y, Stawowczyk M, Chen HM, Yue Z, et al. (2008) Autophagy promotes necrosis in apoptosis-deficient cells in response to ER stress. Cell Death Differ 15: 422-425.
42. Samara C, Tavernarakis N (2008) Autophagy and cell death in Caenorhabditis elegans. Curr Pharm Des 14: 97-115.
43. Gjertsen BT, Bredholt T, Anensen N, Vintermyr OK (2007) Bcl-2 antisense in the treatment of human malignancies: a delusion in targeted therapy. Curr Pharm Biotechnol 8: 373-381.
44. Enyedy IJ, Ling Y, Nacro K, Tomita Y, Wu X, et al. (2001) Discovery of smallmolecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 44: 4313-4324.
45. Heckman CA, Mehew JW, Ying GG, Introna M, Golay J, et al. (2000) A-Myb up-regulates Bcl-2 through a Cdx binding site in t(14;18) lymphoma cells. J Biol Chem 275: 6499-6508.
46. Bouker KB, Skaar TC, Riggins R, Harburger DS, Fernandez DR, et al. (2005) Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis 26: 1527-1535.
47. Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, et al. (1998) In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 41: 385-390.